Compare Amylx Pharmaceuticals Inc (AMLX) vs Firy Inc. (FIRY) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

FIRY (formerly Skillz) trades at $8.54, down 3.06% today, amid a recent rebrand and mixed quarterly results. The stock shows a bullish technical signal with support near $8 and resistance at $9, while fundamentals reveal persistent losses despite a high gross margin of 87.75%. Revenue has declined from $270M in 2022 to $104M in 2025, with net income margins deeply negative. Cash flow remains negative, though operating losses have narrowed from 2022 peaks.

Outlook is cautious; while technicals suggest near-term strength, fundamental challenges from sustained unprofitability and high cash burn pose significant risks. Analyst sentiment is mixed with 60% hold ratings, reflecting uncertainty over the company's turnaround amid competitive pressures in mobile gaming.